Research Center: The Ohio State University
Location: Wexner Medical Center, OH, United States
Lead Researchers: Dr. Alan Davis and Dr. Stacey Armstrong
IRB: This study has been reviewed and approved by The Ohio State Biomedical Sciences Institutional Review Board

Are you a Veteran grappling with persistent Post Traumatic Stress Disorder (PTSD) symptoms? Then, step forward into a potential new chapter of hope and healing. You may be eligible to join a cutting-edge clinical study investigating the therapeutic possibilities of psilocybin.

In the quest for healing and well-being, the research team at The Ohio State University Center for Psychedelic Drug Research and Education is examining this non-traditional treatment, seeking to understand its potential to provide lasting relief from mood disorders and improve quality of life. Your experiences could help unlock new pathways to recovery, not just for you, but for fellow Veterans seeking peace after service. Join now and help advance PTSD research!

• Participants will receive a new potential treatment for PTSD at no cost.
• Participants will be compensated up to $475 for time spent participating in this study.
• Participants may experience improvements in their overall mood and mental well-being.
• Participants will be contributing valuable information that may benefit those with PTSD in the future.
• Participants will be helping to advance medical research.

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you can withdraw at any time.
• Any information that you provide will be kept strictly confidential, except as required by law.
• Qualified health professionals will monitor your health as it relates to the study.

• Individuals aged 21 to 64 years of age who are diagnosed with PTSD
• Must be a US military Veteran
• Must have at least a high school level of education
• Must have tried therapy or medication to treat PTSD
• Must not have a known heart condition
• Must not have a history of seizures
• Must not use nicotine products regularly
• Must not have been diagnosed with Type 1 Diabetes, have a history of Schizophrenia or Bipolar I or II disorder
• Must be able to attend study visits at the research site over approximately 8 to 10 months

The study team will explain the research in its entirety, but some details are:

• After taking the questionnaire and signing a consent form, participants will be required to have up to two or more screening sessions to further confirm eligibility for this study
• Participants will be asked to complete questionnaires and be interviewed about their personal and family medical and psychiatric history. A physical exam will also be conducted, comprising of height, weight, blood pressure, and heart rate measurements, as well as an electrocardiogram (ECG).
• If eligible, participants will be administered psilocybin on two separate occasions. During sessions, participants will spend time in a comfortable room with two guides who will ask the participant to lie down on the couch with eyeshades and headphones through which they can listen to a pre-selected musical program. The study team will monitor participants during and after the psilocybin session before safely allowing participants to leave the research center.

Ohio State University Center for Psychedelic Drug Research & Education
The mission of the Center for Psychedelic Drug Research and Education (CPDRE) is to explore and advance the research about psychedelic drugs and their effects, and to disseminate knowledge about psychedelics through education initiatives at the college, university, and local, national, and international locations.